{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:02:59Z","timestamp":1747202579149,"version":"3.40.5"},"reference-count":12,"publisher":"Ordem dos Medicos","issue":"1","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Port"],"abstract":"<jats:p>A leucemia miel\u00f3ide aguda (LMA) \u00e9 uma neoplasia hematol\u00f3gica caracterizada pela prolifera\u00e7\u00e3o clonal, com incid\u00eancia crescente com a idade. A LMA com altera\u00e7\u00f5es relacionadas com mielodisplasia (LMA-ARM) representa um subtipo de LMA com progn\u00f3stico adverso, cujo tratamento \u00e9 desafiante, sobretudo nos doentes mais idosos. Descrevemos o caso de uma doente de 77 anos com o diagn\u00f3stico de LMA-ARM, de alto risco ineleg\u00edvel para quimioterapia intensiva, com necessidades transfusionais frequentes. Tanto quanto \u00e9 do seu conhecimento, os autores apresentam o primeiro caso cl\u00ednico de LMA-ARM, em Portugal, tratado com a associa\u00e7\u00e3o do agente hipometilante, azaciditina, e o inibidor BCL2 (venetoclax), o que foi crucial para o tratamento e sobreviv\u00eancia global do doente, muito al\u00e9m da sobreviv\u00eancia esperada.<\/jats:p>","DOI":"10.20344\/amp.17770","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:50:50Z","timestamp":1648561850000},"page":"59-62","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax: Uma Nova Esperan\u00e7a para o Doente Idoso com Leucemia Miel\u00f3ide Aguda"],"prefix":"10.20344","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-6152","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Marques","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Em\u00edlia","family":"Cortes\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8464","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","key":"1532","DOI":"10.1056\/NEJMra1406184"},{"doi-asserted-by":"crossref","unstructured":"Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf, Garelius H, et al. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia. 2017;31:728\u201331.","key":"1533","DOI":"10.1038\/leu.2016.312"},{"doi-asserted-by":"crossref","unstructured":"\u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva I, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol. 2015;33:3641\u20139.","key":"1534","DOI":"10.1200\/JCO.2014.60.0890"},{"doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","key":"1535","DOI":"10.1182\/blood-2016-03-643544"},{"doi-asserted-by":"crossref","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:697\u2013712.","key":"1536","DOI":"10.1016\/j.annonc.2020.02.018"},{"doi-asserted-by":"crossref","unstructured":"Arber DA, Erba HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020;154:731\u201341.","key":"1537","DOI":"10.1093\/ajcp\/aqaa107"},{"doi-asserted-by":"crossref","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291\u20139.","key":"1538","DOI":"10.1182\/blood-2015-01-621664"},{"doi-asserted-by":"crossref","unstructured":"Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B. AML with myelodysplasia-related changes: Development, challenges, and treatment advances. Genes. 2020;11:1\u201313.","key":"1539","DOI":"10.3390\/genes11080845"},{"doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","key":"1540","DOI":"10.1182\/blood-2016-08-733196"},{"doi-asserted-by":"crossref","unstructured":"Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91:1861\u201370.","key":"1541","DOI":"10.1007\/s00277-012-1537-8"},{"doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatmentnaive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","key":"1542","DOI":"10.1182\/blood-2018-08-868752"},{"doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329.","key":"1543","DOI":"10.1056\/NEJMoa2012971"}],"container-title":["Acta M\u00e9dica Portuguesa"],"original-title":[],"link":[{"URL":"https:\/\/actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/17770\/6596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/17770\/6596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T11:51:04Z","timestamp":1672660264000},"score":1,"resource":{"primary":{"URL":"https:\/\/actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/view\/17770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,2]]}},"URL":"https:\/\/doi.org\/10.20344\/amp.17770","relation":{},"ISSN":["1646-0758","0870-399X"],"issn-type":[{"type":"electronic","value":"1646-0758"},{"type":"print","value":"0870-399X"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}